MedTrace Logo

A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment

NCT01257178 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2011-06-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of hepatic dysfunction on the pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.

Conditions

Interventions

DRUG

LY2624803

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Germany
  • Hungary
  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01257178 on ClinicalTrials.gov